Table 1.
Sociodemographic and clinical characteristics of drug-susceptible and drug-resistant patients at inclusion.
| N | ALL | DS-TB | DR-TB | p |
|---|---|---|---|---|
| 132 | 104 | 28 | ||
| Patient demographics | ||||
| Age (years) | 27 (21–36.2) | 27 (21–37.2) | 27.5 (19.7–33.2) | 0.41 |
| Sex (male) | 62.9% (83/132) | 64.4% (67/104) | 57.1% (16/28) | 0.51 |
| Treatment outcome | ||||
| Cured and completed | 95.5% (126/132) | 94.2% (98/104) | 100% (28/28) | 0.34 |
| Completed | 1.5% (2/132) | 1.9% (2/104) | 0 | - |
| Failure | 2.3% (3/132) | 2.9% (3/104) | 0 | - |
| Relapse | 0.8% (1/132) | 1% (1/104) | 0 | - |
| Country of origin | ||||
| Bangladesh | 28.8% (38/132) | 20.2% (21/104) | 60.7% (17/28) | >0.001 |
| Georgia | 23.5% (31/132) | 20.2% (21/104) | 35.7% (10/28) | 0.13 |
| Lebanon | 5.3% (7/132) | 6.7% (7/104) | 0 | 0.34 |
| Madagascar | 27.3% (36/132) | 34.6% (36/104) | 0 | >0.001 |
| Paraguay | 15.2% (20/132) | 18.3% (19/104) | 3.6% (1/28) | 0.073 |
| BMI at inclusion | 18.7 (16.9–21.3) | 18.83 (16.9–21.4) | 18.7 (17.5–21.0) | 0.79 |
| WBC absolute count at inclusion (cells/mm3) | 9745 (7365–12032) | 9695 (7350–12055) | 10150 (7725–11850) | 0.65 |
| Neutrophils at inclusion (% of WBC) | 75 (68–79.1) | 75 (68.3–79) | 78 (66.7–80.2) | 0.34 |
| Lymphocytes at inclusion (% of WBC) | 18 (14–25) | 18 (14–25) | 17 (13.7–24.5) | 0.52 |
| Monocytes at inclusion (% of WBC) | 4.4 (2–7) | 5 (2–8.0) | 4 (3–5.2) | 0.42 |
| Number of household contacts | 4 (3–6) | 4 (3–6) | 4 (3.75–6.2) | 0.86 |
| BCG vaccination | 86.2% (94/109) | 86.4% (76/88) | 85.7% (18/21) | 1 |
| Risk factors and comorbidities | ||||
| Smoking | 46.2% (61/132) | 46.2% (48/104) | 46.4% (13/28) | 1 |
| Alcohol abuse | 22% (29/132) | 24% (25/104) | 14.3% (4/28) | 0.57 |
| Injectable drug use | 3.8% (5/131) | 2.9% (3/104) | 7.4% (2/27) | 0.27 |
| Jail detention history | 8.5% (11/130) | 9.8% (10/102) | 3.6% (1/28) | 0.57 |
| Chronic HCV infection | 1.6% (2/129) | 2% (2/101) | 0 | 0.75 |
| Other disease1 | 6.2% (7/113) | 7.8% (7/90) | 0 | 0.34 |
| History of TB | ||||
| Prior exposure to active TB patients | 29% (38/131) | 29.1% (30/103) | 28.6% (8/28) | 0.23 |
| Documented previous TB episode | 15.1% (20/132) | 11.5% (12/104) | 28.5% (8/28) | 0.048 |
| Previous TB outcome | ||||
| Cured and completed | 61.1% (11/18) | 61.5% (8/13) | 60% (3/5) | 1 |
| Treatment completed | 11.1% (2/18) | 7.7% (1/13) | 20% (1/5) | 0.49 |
| Outcome not evaluated or unknown | 16.7% (3/18) | 15.4% (2/13) | 20% (1/5) | 1 |
| Treatment failure | 11.1% (2/18) | 15.4% (2/13) | 0 | - |
Data are given as % (N) or median (interquartile range). DS-TB, drug-susceptible tuberculosis; DR-TB, drug-resistant tuberculosis; BMI, body mass index; WBC, white blood cells; 1: asthma, hypertension, inflammation. P-values are given for DS-TB vs. DR-TB.
No patients had HIV, non-TB chronic pulmonary diseases, renal diseases, solid tumors, chronic HBV infection, were pregnant, or under immunosuppressive therapies (corticosteroids, calcineurin inhibitors, biologics).